Atossa Therapeutics Inc

Atossa Therapeutics Inc maintains a strong liquidity position, with cash and equivalents amounting to $79.53 million, representing 92.7% of total assets. The company has no long-term debt and a current ratio of 14.35, indicating a robust ability to meet short-term obligations. However, the company reported negative operating and net income of $7.11 million and $6.05 million, respectively, in the latest period. The price-to-book ratio of 0.55 suggests the market values the company at a discount to its book value, while the price-to-tangible-book ratio is identical, indicating no intangible asset premium. Profitability metrics are negative, with a return on equity of -7.55% and a return on assets of -7.05%, both significantly below industry norms for biotechnology firms. The company's operating cash flow of -$9.23 million and free cash flow of -$6.05 million highlight ongoing cash burn despite strong liquidity reserves. These figures suggest the company is in a growth or development phase, with limited revenue generation to offset R&D and operational costs. Geographically, Atossa's revenue concentration is not disclosed in the available data, but the company's operations are primarily based in the United States. The firm's business is not segmented into multiple product lines or geographic regions in the latest financial report, making it difficult to assess diversification risk. However, the company's focus on breast cancer diagnostics and therapeutics suggests a niche market exposure. The company's growth trajectory is uncertain, with no specific revenue growth projections provided in the latest data. The absence of capital expenditures beyond $9,000 indicates minimal investment in physical infrastructure, which is typical for a biotechnology firm in the R&D phase. The company's shares outstanding have remained stable, with no dilution observed in the latest period. Risk factors include the company's reliance on successful clinical trials and regulatory approvals for its pipeline products. The risk assessment indicates low liquidity and dilution risk, with no immediate filing-based flags detected. However, the company's negative net income and cash flow suggest ongoing operational risks, particularly if clinical milestones are not met or if capital is required for further development. Recent events include analyst price targets ranging from $20 to $25, with a mean of $23 and a median of $24. The mean recommendation is 2.00, indicating a "Buy" consensus. No recent filings or transcripts were provided in the data, so no specific events can be cited for the latest period.